The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...
The rollout marks a major step in reducing childhood deaths from sickle cell disease through early screening and advanced ...
Recent peer-reviewed study supports what patients shared with their own voices: Automated red blood cell exchange improves the lives of people struggling with sickle cell disease LAKEWOOD, Colo., Nov.
Following the U.S. FDA’s March 11 approval of Novo Nordisk A/S’ glucagon-like peptide 1 receptor agonist, Wegovy (semaglutide), to reduce the risk of major ...
In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...
* FDA - ISSUED EUA TO TERUMO BCT INC. , MARKER THERAPEUTICS AG FOR THEIR SPECTRA OPTIA APHERESIS SYSTEM & DEPURO D2000 ADSORPTION CARTRIDGE DEVICES Source text for Eikon: ...
The company identified 7 studies from the clinical evidence search which incorporated an economic analysis. However, it was unable to draw any firm conclusions from these studies. The external ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results